Novartis And MSD Triumph At The 14th Annual Scrip Awards

The pharma, biotech and allied industries came together to celebrate another year of excellence at the 14th Annual Scrip awards in London on Nov. 28, hosted by the Right Honourable Lord (William) Hague.

Scrip Awards 2018
The 2018 Winners • Source: Scrip | Informa 2018

The past year has been another one of change. Those in the industry know that R&D innovation is driving more activity in the sector than ever before. As biosimilars gradually increase their place on the market and payers worldwide demand price restraints, we've seen industry renewal through the development and launch of a number of new therapy modes that truly offer tremendous value to patients and society, from gene and cell therapies to continuing advances in immuno-oncology. Meanwhile, data and artificial intelligence tools are helping to drive transformation across the industry's activities. A glance at the winners of the 2018 Scrip Awards show that the future is bright for biopharma.

The Scrip Awards categories range from those that reward the broader achievements of companies, to those for innovation in deal...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

Test

Sponsored by :

Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.